Karen S Lynch
CIK 1333760 · President and CEO · last filed 2026-05-22
Karen S Lynch is a President and CEO who has filed 92 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for TMO, was dated May 22, 2026. Across all open-market trades the lifetime net is −$9.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $17.7M across reported positions. 2 SEC filings were submitted jointly with AUTOMATIC DATA PROCESSING INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$17.67M
6
92
-$9.73M
Filer Profile
RW61
HARTFORD, CT 06156
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TMO | Director | 1,235 | $613.78 | $758.0K | $0 | 8 | 2026-05-22 |
| ADP | Director | 1,535 | $277.62 | $426.1K | $0 | 1 | 2025-11-14 |
| CVS | President and CEO | 74,687 | $96.74 | $7.23M | -$5.03M | 19 | 2024-04-03 |
| USB | Director | — | $63.37 | — | $0 | 13 | 2021-12-20 |
| MAGELLAN HEALTH INC (MGLN) Delisted | President | 4,896 | $94.99 | $465.1K | -$3.89M | 13 | 2012-03-07 |
| CI | Pres. Grp Ins Dntl Vis & Pharm | 32,770 | $282.52 | $9.26M | -$802.8K | 11 | 2009-06-26 |
Recent Filings
92 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-22 | TMO | Grant (A) | +499 | $0 | EDGAR |
| 2026-03-31 | TMO | Grant (A) | — | $0 | EDGAR |
| 2026-01-05 | TMO | Grant (A) | — | $0 | EDGAR |
| 2025-11-14 | ADP | Grant (A) | +1,453 | $0 | EDGAR |
| 2025-09-30 | TMO | Grant (A) | — | $0 | EDGAR |
| 2025-07-01 | TMO | Grant (A) | — | $0 | EDGAR |
| 2025-05-22 | TMO | Grant (A) | +565 | $0 | EDGAR |
| 2025-04-01 | TMO | Grant (A) | — | $0 | EDGAR |
| 2025-02-21 | TMO | Grant (A) | +95 | $0 | EDGAR |
| 2024-04-03 | CVS | Mixed | −16,705 | -$1.33M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.